The Azerbaijani pharmaceutical plant "R-PHARM" has signed an agreement with the Russian company Gerof

Pharmaceutical plant "R-PHARM" expands product line

LLC "R-Pharm" (part of the "R-Pharm" Group of companies) and the Russian biotechnology company GEROPHARM announced a strategic partnership in the field of localization of drugs for the treatment of socially significant diseases in Azerbaijan.

The agreement between the parties involves the localization of three types of insulin at the "R-Pharm" plant in Azerbaijan: RinGlar (insulin glargine), RinFast (insulin aspart), RinFast Mix (biphasic insulin aspart), as well as the beginning of commercial sales of drugs for the treatment of diabetes mellitus.

At the moment, the first production campaign of localized insulins has been carried out, and the drugs have already been introduced into civil circulation.

"The localization of insulin production in Azerbaijan is an important step towards increasing the availability of vital medicines for patients. The release of the first batch of insulins confirms our readiness to continue providing the market with quality drugs," noted Natalia Badanina, General Director of the "R-Pharm" plant.

According to the State Statistics Committee, in 2023 the number of diabetes patients in Azerbaijan reached more than 320 thousand people, of which 30 thousand patients were diagnosed with insulin-dependent diabetes. The Russian-Azerbaijani partnership aims to increase the availability of modern and effective medicines for citizens suffering from this disease.

The localization of production of foreign pharmaceutical products in Azerbaijan is an important stage that helps provide local patients with high-quality medications that meet international standards.

"GEROPHARM is the largest full-cycle insulin manufacturer in the CIS, and we are ready to share our expertise in this matter with partners. We hope that our joint efforts with R-Pharm will make a significant contribution to strengthening Azerbaijan's national healthcare and improving the quality of life for patients with diabetes," emphasized Petr Rodionov, CEO of GEROPHARM.

The first pharmaceutical plant in Azerbaijan, "R-Pharm," has been operating in the Pirallahi Industrial Park since 2019. The production complex is one of the most modern plants in the CIS, including production, laboratory, and logistics units. The enterprise area is 4.6 hectares, and the production capacity exceeds 250 million units of products per year.

GEROPHARM is an international manufacturer of biotechnological products

in accordance with GxP standards. Today, the company's portfolio includes original drugs, biosimilars of human genetically engineered insulins and insulin analogs, as well as generics – a total of more than 35 medicines. GEROPHARM ranks 1st in the Russian insulin market and is among the TOP-10 insulin manufacturers in the world. The company's products are represented in Russia and 14 countries of the near and far abroad.

The new collaboration between "R-Pharm" and GEROPHARM is a significant step in the development of the republic's pharmaceutical sector and improving the quality of medical care for the population.